GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Cash Flow from Operations

Surmodics (Surmodics) Cash Flow from Operations : $25.8 Mil (TTM As of Mar. 2024)


View and export this data going back to 1998. Start your Free Trial

What is Surmodics Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Mar. 2024, Surmodics's Net Income From Continuing Operations was $0.2 Mil. Its Depreciation, Depletion and Amortization was $2.1 Mil. Its Change In Working Capital was $2.9 Mil. Its cash flow from deferred tax was $-0.1 Mil. Its Cash from Discontinued Operating Activities was $0.0 Mil. Its Asset Impairment Charge was $0.0 Mil. Its Stock Based Compensation was $2.1 Mil. And its Cash Flow from Others was $0.2 Mil. In all, Surmodics's Cash Flow from Operations for the three months ended in Mar. 2024 was $7.4 Mil.


Surmodics Cash Flow from Operations Historical Data

The historical data trend for Surmodics's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Cash Flow from Operations Chart

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.04 14.01 15.39 -17.22 10.51

Surmodics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.83 25.89 1.25 -8.79 7.42

Surmodics Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Surmodics's Cash Flow from Operations for the fiscal year that ended in Sep. 2023 is calculated as:

Surmodics's Cash Flow from Operations for the quarter that ended in Mar. 2024 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surmodics  (NAS:SRDX) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Surmodics's net income from continuing operations for the three months ended in Mar. 2024 was $0.2 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Surmodics's depreciation, depletion and amortization for the three months ended in Mar. 2024 was $2.1 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Surmodics's change in working capital for the three months ended in Mar. 2024 was $2.9 Mil. It means Surmodics's working capital increased by $2.9 Mil from Dec. 2023 to Mar. 2024 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Surmodics's cash flow from deferred tax for the three months ended in Mar. 2024 was $-0.1 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Surmodics's cash from discontinued operating Activities for the three months ended in Mar. 2024 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Surmodics's asset impairment charge for the three months ended in Mar. 2024 was $0.0 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Surmodics's stock based compensation for the three months ended in Mar. 2024 was $2.1 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Surmodics's cash flow from others for the three months ended in Mar. 2024 was $0.2 Mil.


Surmodics Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Surmodics's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines

From GuruFocus

Surmodics Receives FDA Approval for the SurVeil� Drug-Coated Balloon

By Business Wire Business Wire 06-20-2023